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                                         INTRODUCTION
Portal hypertension manifesting as gastrointestinal bleed is common in 30% 
of cirrhotic patients, with a one year mortality of 50% after the initial bleed.1-6 The 
greatest risk is during the first  48 to 72 hours and more than 50% of all  early 
rebleed  episodes  occur  within  the  first  10  days  after  cessation  of  active 
hemorrhage.7-9
While most of the reports on the variceal bleed pattern are from the West, little 
information is available from the Southern states of the Indian subcontinent. A 
preliminary observation from our center in 2003 had shown a low rebleed rate 
after the index bleed.10 This study had a drawback of inclusion of bleeders who 
were already on treatment and there was probably a bias towards a low rebleed 
rate.
The  present  study  was  undertaken  to  prospectively  assess  the  variceal  bleed 
pattern  and  its  attendant  complications  amongst  cirrhotics  with  portal 
hypertension.  Ethics  committee  of  Institution  approved  the  undertaking  of  the 
study.
                                        
                                             
                                           AIMS AND OBJECTIVES
1. To determine variceal pattern amongst south Indian patients with cirrhosis 
liver 
2. To study the prevalence of recurrent bleed
3. To study the risk factors that predicts an index bleed and subsequent bleed.
  
REVIEW OF LITERATURE
Anatomic features portal venous system:
The portal venous system, formed by the confluence of the superior mesenteric 
vein and the splenic vein which drains the stomach, the large and small intestine, 
the pancreas, and the spleen. An important feature of this system is that a number 
of its tributaries also communicate with the systemic circulation. These include the 
intrinsic and extrinsic veins of the gastroesophageal junction; hemorrhoidal veins 
of the anal canal; paraumbilical veins and the recanalized falciform ligament; the 
splenic venous bed and the left renal vein; and the retroperitoneum. 
In  portal  hypertension,  these  venous collaterals  dilate  and allow portal  venous 
blood  to  return  to  the  systemic  circulation.  Clinically,  the  most  significant 
collaterals  are  the  intrinsic  veins  of  the  gastroesophageal  junction,  which  are 
located close to the mucosal surface. They are the collaterals most likely to bleed 
when dilated because of increased blood flow. 
The veins of the gastroesophageal junction are classified as intrinsic, extrinsic, and 
venae comitantes. The intrinsic veins form a subepithelial and submucosal plexus 
starting  at  the  gastric  cardia  (upper  stomach)  and  running  the  length  of  the 
esophagus. In healthy persons, these veins drain into the extrinsic plexus through 
perforating veins 2 to 3 cm above the gastroesophageal junction. Flow through the 
perforating  veins  is  unidirectional  toward  the  extrinsic  plexus  and  systemic 
circulation.  When  portal  hypertension  develops,  however,  the  valves  of  the 
perforating  veins  become  incompetent  and  allow  reversal  of  flow  from  the 
extrinsic to the intrinsic system. 
Varices  of  the  gastroesophageal  junction  usually  are  classified  by  location  as 
esophageal or gastric. Esophageal varices consist of three or four large trunks that 
are further characterized by size. This classification is important because the larger 
the varix, the more likely it is to bleed. Gastric varices, on the other hand, are by 
convention  classified  only  by  location.  Most  likely  to  bleed  are  the  isolated 
variceal clusters of the fundus, which often are caused by splenic vein thrombosis 
or spontaneous splenorenal collaterals.
Pathophysiology of portal hypertension:
Portal pressure can be measured only angiographically and is expressed in terms 
of hepatic venous pressure gradient (HVPG). HVPG is the difference between the 
wedged hepatic venous pressure and the free hepatic venous pressure. The former 
is a reflection of sinusoidal pressure, and the latter is a correction for the effects of 
intra-abdominal pressure (eg, tense ascites). Portal pressure is directly related to 
portal venous inflow and the degree of outflow resistance; it can be expressed in 
terms of Ohm's law as follows: 
Portal pressure = portal venous inflow x outflow resistance 
The  initiating  event  in  the  development  of  portal  hypertension  is  increased 
resistance to portal outflow. Some causes and sites of the increased resistance are 
listed below. 
• Prehepatic
o Splenic vein thrombosis
o Portal vein thrombosis
o Extrinsic compression of the portal vein
• Intrahepatic
o Congenital hepatic fibrosis
o Hepatic peliosis
o Idiopathic portal hypertension
o Sclerosing cholangitis
o Tuberculosis
o Schistosomiasis
o Primary biliary cirrhosis
o Alcoholic cirrhosis
o Hepatitis B virus–related and hepatitis C virus–related cirrhosis
o Wilson disease
o Hemachromatosis
o Alpha-1 antitrypsin deficiency
o Chronic active hepatitis 
o Fulminant hepatitis
• Posthepatic
o Budd-Chiari syndrome 
o Thrombosis of the inferior vena cava 
o Constrictive pericarditis 
o Venoocclusive disease of the liver
In cirrhosis, portal hypertension is aggravated by the increase in the portal venous 
inflow due to splanchnic vasodilation. When portal pressures rise, blood flow is 
diverted to venous collaterals that dilate to form varices. The likelihood that any 
one  varix  will  rupture  and  bleed  depends  on  its  wall  tension,  which  can  be 
determined by the application of Poiseuille's and Laplace's laws. In practice, this 
means that a large, long varix with a high flow rate and a thin wall is most likely 
to rupture and bleed. Because it is not feasible to shorten a varix or increase its 
wall  thickness,  therapies for portal  hypertension aim to decrease variceal flow. 
This  decrease  is  achieved  by  reducing  either  portal  venous  inflow  (eg,  by 
splanchnic vasoconstriction) or resistance to portal outflow (eg, by creation of a 
shunt). 
Natural history of varices:
The natural history of varices in cirrhotic patients with portal hypertension evolves 
from a patient without varices to the patient that develops varices to the patient 
that develops variceal hemorrhage. Varices and variceal hemorrhage are a direct 
consequence  of  portal  hypertension.  Gastroesophageal  varices  are  present  in 
approximately 50% of cirrhotic patients when endoscopy is performed at the time 
of the diagnosis of cirrhosis. Their presence correlates with the severity of liver 
disease; while only 40% of Child A patients has varices, they are present in 85% 
of  Child  C patients.  (11)  Patients  with varices almost invariably  have a  portal 
pressure (as  determined by the hepatic venous pressure gradient [HVPG] of at 
least 12 mm Hg, while normal HVPG is 3–5 mm Hg. (4, 12) Initially varices are 
small, but they enlarge with increasing blood flow. When a varix enlarges and the 
tension in its wall exceeds the expanding force, rupture occurs, leading to the most 
deadly complication of cirrhosis,  variceal hemorrhage. This  complication has a 
high risk of recurrence. In patients without them, varices develop at a rate of 8% 
per year. (13,14) and factors associated with this progression are the presence of 
decompensated cirrhosis (Child B/C), alcoholic etiology, and presence of red wale 
marks at the time of baseline endoscopy.(13) Variceal hemorrhage occurs at a rate 
of 5%–15% per year and the most important predictor of hemorrhage is the size of 
varices,  with the  highest  risk of  first  hemorrhage (15% per  year)  occurring  in 
patients  with large  varices.  Other  predictors  of hemorrhage are  decompensated 
cirrhosis  (Child  B/C)  and the  presence of  red wale  marks  on  endoscopy.  (15) 
Although bleeding from esophageal varices ceases spontaneously in up to 40% of 
patients, the mortality of an episode of variceal hemorrhage is of at least 20% at 6 
weeks, and it occurs mostly in patients with severe liver disease and in those with 
early  re-bleeding.  Late  rebleeding  occurs  in  approximately  60%  of  untreated 
patients within 1–2 years of the index hemorrhage. (4,16) 
Portal  pressure  directly  can only  be  measured by  invasive  methods.  The  most 
commonly used technique involves the catheterization of the hepatic vein via a 
transfemural or a transjugular route. By subtracting the free hepatic vein pressure 
from  the  wedged  hepatic  venous  pressure,  the  hepatic  vein  pressure  gradient 
(HVPG)  can  be  calculated,  which  is  an  indirect  but  precise  estimate  of portal 
pressure. The normal upper limit of the HVPG is 5 mmHg. (12,13) Values above 
this limit denote portal hypertension. 
 
Clinically significant portal hypertension (CSPH) indicates the pressure level at 
which a patient is at high risk of developing complications and therefore should 
receive prophylactic treatment. Varices do not occur and do not bleed if the HVPG 
is  below a  threshold  value  of  10-12 mmHg.  As  a  consequence,  the  following 
definition of CSPH has been given at a recent international consensus workshop 
(20).  “CSPH  is  defined  by  an  increase  in  HVPG  to  a  threshold  above 
approximately  10  mmHg.  The  presence  of  varices,  variceal  hemorrhage, 
and/or ascites  is  indicative  of  the  presence  of  CSPH”.  Thus,  the  policy  of 
identifying and monitoring patients with portal hypertension should be primarily 
targeted on patients with CSPH.  
Screening for esophageal varices:
Effective prophylactic treatments  to prevent variceal bleeding exist for patients 
with esophageal varices. (4) There are no reliable methods of predicting which 
cirrhotic  patients  will  have  esophageal  varices  without  endoscopy.(17)  An 
American  Association  for  the  Study  of  Liver  Diseases  guideline  suggests  that 
patients  with  Child’s  stage  A liver  cirrhosis  and  signs  of  portal  hypertension, 
specifically a platelet count of less than 140,000/mm , and/or enlarged portal vein 
diameter of greater that 13 mm or those classified as Child’s B or C at diagnosis 
should have screening endoscopy.(18)  Patients with cholestatic disease may have 
portal hypertension with relatively preserved liver function and platelet counts. A 
retrospective  study of  235 patients  concluded that  patients  with either  primary 
biliary  cirrhosis  or  primary  sclerosing  cholangitis  who  have  a  platelet  count 
200/mm(4) , an albumin level 40 gm/L, and a bilirubin level 20 mmol/L should be 
screened for esophageal varices. (19) Other groups recommend screening for all 
patients  diagnosed  with  cirrhosis.(20)  The  optimal  surveillance  intervals  for 
esophageal  varices  have  not  been  determined.  For  patients  found  to  have  no 
varices on ini-tial screening endoscopy, repeat endoscopy at 3-year intervals has 
been suggested, whereas patients with small varices should undergo endoscopy in 
1 to 2 years. (20) Esopha- geal varices may grow faster in patients with cirrhosis 
secondary  to  alcohol  abuse  or  severe  liver  impairment  and  in  those  with 
endoscopic stigmata of high risk (‘‘red wale markings’’); this subgroup of patients 
should undergo yearly upper endoscopy. 
Concerning abdominal ultrasound and Doppler studies, inter-observer and inter-
equipment variability limit their applicability in clinical practice. Thus, the current 
recommendation (20) is that the accuracy of non-invasive tests (such as Doppler 
ultrasound) for  the diagnosis of clinically significant portal hypertension should 
be further assessed before their use can be recommended in clinical practice. As a 
consequence,  upper  GI  endoscopy is  the  main  tool  used  for  screening  and 
monitoring patients.
Preventing the development of varices:
The reduction in portal pressure induced by b-adrenergic blockers has been shown 
experimentally  to  prevent  the  development  of  portosystemic  collaterals.  (22) 
Endoscopic screening for varices should be performed in all patients with cirrhosis 
and, in those patients without varices, b-blockers are not recommended. (21) In 
these  patients,  endoscopy  should  be  repeated  in  2–3  years,  sooner  if  there  is 
evidence of hepatic decompensation.
Preventing first variceal hemorrhage in patents with varices:
Current guidelines recommend prophylactic therapy with nonselective b-blockers 
(propranolol,  nadolol)  to  prevent  first  variceal  hemorrhage in  cirrhotic  patients 
with medium- to large-sized esophageal varices on screening endoscopy. Although 
the risk of first hemorrhage with b-blocker therapy is significantly decreased, it is 
not  eliminated.  Furthermore,  b-blockers  cause  side  effects  in  ~20%  of  cases, 
leading to discontinuation of treatment in ~12% of patients. (23) 
EVL is  slightly  better  than  b-blockers  for  prevention of  a  first  variceal  bleed. 
However, given controversial results from incomplete trials, the recommendations 
of the Baveno conference still stand, that is, that nonselective b-blockers are first 
line therapy in the prevention of first  variceal hemorrhage and EVL should be 
offered  to  patients  with large  varices  who are  not  candidates  for  long-term b-
blocker therapy. (21) An additional  recommendation should be to initiate EVL 
before or promptly after discontinuation of b-blockers in those who cannot tolerate 
these  drugs.  Early  beta-blocker  therapy may slow the  rate  of  growth of  small 
esophageal varices. (24) Endoscopic sclerotherapy (EST) is not recommended for 
primary prophylaxis. (25,26) While several studies have shown benefit,  a well-
done US study showed an increased mortality rate in the treated group.
Lab Studies: 
• Complete  blood  count:  Results  may  show  anemia,  leucopenia,  and 
thrombocytopenia in patients with cirrhosis. Anemia may be secondary to 
bleeding, nutritional deficiencies, or bone marrow suppression secondary to 
alcoholism. Many patients with portal hypertension have some degree of 
hypersplenism. The hematocrit  value may be low in patients with upper 
abdominal bleeding.
• Type and crossmatch blood and reserve 6 units of packed red blood cells.
• Prothrombin time: Because the coagulation factors involved in this test are 
synthesized by the liver, impairment of the liver function may result in a 
prolonged prothrombin time.
• Liver function tests: A mild elevation of the plasma activity of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) may occur in 
cirrhosis, although activity may be normal.
• Blood urea, creatinine, and electrolytes: Blood urea and creatinine levels 
may  be  elevated  in  patients  with  esophageal  bleeding.  Drug  treatment, 
cirrhosis, ascites, and blood loss may contribute to changes in the serum 
electrolytes of these patients.
• Arterial blood gas and pH measurements
• Hepatic serology helps in the assessment of the cause of cirrhosis.
Imaging Studies: 
• Ultrasound of the upper abdomen may be indicated, especially if  biliary 
obstruction or liver cancer is suspected.
Other Tests: 
• Rectal examination: Obtain a stool sample for visual inspection. A black, 
soft, tarry stool on the gloved examining finger suggests upper GI bleeding
Treating acute variceal hemorrhage: 
Regarding non-specific management, current guidelines recommend prophylactic 
antibiotic therapy for cirrhotic patients admitted with acute variceal hemorrhage 
and  should  be  instituted  from  admission.  (21)  The  recommended  specific 
management  consists  of  the  combination  of  endoscopic  therapy  plus  a  safe 
vasoactive drug (terlipressin or analogues,  somatostatin or  analogues (21).  The 
advantage  of  these  drugs  is  that  they  can  be  started  at  admission  and  before 
diagnostic/  therapeutic endoscopy and continued for  2–5 days to prevent early 
variceal re-bleeding. Baik et al. (28) suggested that 2 mg IV terlipressin may be of 
greater benefit than somatostatin and its analogues. Although both drugs decreased 
HVPG significantly, the effect of terlipressin was sustained over the 25-minute 
duration of the study while the effect of octreotide was transient having shown a 
maximal effect at the first minute (decrease of 45% from baseline); however, the 
HVPG had returned to baseline as of the 5-minute time point. 
Regarding  the  best  endoscopic  therapy  for  the  control  of  acute  variceal 
hemorrhage, a meta-analysis of 10 randomized controlled trials shows an almost 
significant  benefit  of  EVL  in  the  initial  control  of  bleeding  compared  to 
sclerotherapy. (27) and also sclerotherapy is associated with an increase in HVPG 
that was maintained throughout the 5-day period of the study, while EVL was 
associated with only a transient increase in HVPG that returned to pretreatment 
values within 48 hours. (29) Therefore, in the Baveno consensus report, EVL is 
the  recommended  form  of  endoscopic  therapy  for  acute  esophageal  variceal 
bleeding although sclerotherapy is recommended if EVL is technically difficult. 
(21) Failures of initial therapy with combined pharmacological and endoscopic 
therapy are best managed by a second attempt at endoscopic therapy or, in the case 
of  fundal  gastric  varices,  by  the  transjugular  intrahepatic  portosystemic  shunt 
(TIPS). (21) 
Preventing recurrent variceal hemorrhage:
Either  combination  pharmacological  therapy  (nonselective  b-blockers  plus 
nitrates) or EVL are considered the therapy of choice in the prevention of variceal 
re-bleeding. The choice depends on tolerance and local expertise. However, with 
either of these therapies, re-bleeding rates are still quite high (30%–42% in studies 
of  b-blockers plus nitrates;  20%–43% with EVL).  (16)  The lowest  re-bleeding 
rates of 7%–13% have been described in studies on pharmacological therapy in 
which HVPG decreases by >20% from baseline or to levels below 12 mm Hg (16) 
Randomized controlled trials show combining EVL and b-blockers significantly 
reduces re-bleeding rates than EVL alone. (30,31) Additionally, 1-year variceal 
recurrence was lower in the EVL + nadolol group (54%) than in the EVL group 
(77%). Therefore the current recommendation is still to use EVL or b-blocker + 
nitrates as first line therapy, recognizing that combination EVL+ b-blocker may be 
a more effective therapy. (21)
Side effects of EVL include hemorrhage from ulcers, chest pain, dysphagia, and 
odynophagia.  Because  gastric  acid  may  exacerbate  post-EVL  ulcers,  acid 
suppressors may reduce EVLrelated side effects. (32)  
In  patients  who  fail  combined  endoscopic  and  pharmacological  treatment  for 
prevention  of  re-bleeding,  TIPS  or  surgical  shunts  should  be  considered, 
depending on local availability and the surgical candidacy of the patient. Patients 
with decompensated cirrhosis are not candidates for shunt therapy and should be 
evaluated for liver transplantation.
Endoscopic Sclerotherapy:
Endoscopic sclerotherapy for variceal bleeding, although described in 1939 (33), 
was  "rediscovered"  in  the  late  1970s.  Soon  it  became evident  that  ongoing 
hemorrhage from a varix could be stopped by the injection of various chemical 
agents, that this form of intervention decreased the volume of blood transfused, 
and that additional injection sessions decreased the number of episodes of recurrent 
bleeding.  Sclerotherapy  may  sometimes  be  equal or  perhaps  even  superior  to 
portacaval  or  selective  splenorenal shunt  surgery  in  terms  of  survival  and  the 
preservation of hepatic function (34-36). The results of one trial (37) indicate that 
endoscopic sclerotherapy decreases the mortality  for patients  with cirrhosis and 
variceal bleeding; however, another trial (38) did not find a decrease in mortality. 
A meta-analysis  of  seven trials  revealed that  overall  survival  for  patients  with 
variceal bleeding was improved by sclerotherapy (39).  Thus, it  appeared that a 
definitive treatment for this major complication of portal hypertension had been 
found. This is not entirely true, but sclerotherapy has become a major technique 
used  in  the  management  of  variceal hemorrhage,  and  it  has  benefited  patients 
greatly.
However,  endoscopic  sclerotherapy  has  limitations.  The  injection of  a  noxious 
agent  into any segment  of  the  human vascular  system raises  the  possibility  of 
untoward effects in organs at a distance from the primary site of injection. The 
potential  risk  for  such complications  would  depend  to  an  extent  on  variceal 
anatomy. Unfortunately,  only a few studies (40-42) exist  of normal esophageal 
venous and variceal anatomy and of the nature of blood flow in these structures. 
Those studies that are available suggest that an injected sclerosing agent may reach 
virtually  any  organ. This  has  been  substantiated  by  many  reports  of  untoward 
events after sclerotherapy, some with serious consequences, in organ systems other 
than  the  esophagus.  In  particular,  an  appreciable risk  exists  for  sepsis  after 
sclerotherapy. Although these "systemic" complications are relatively rare,  they 
represent an important shortcoming for endoscopic sclerotherapy.
Endoscopic sclerotherapy is less than ideal as a therapeutic measure because tissue 
injury is fundamental to its mechanisms of action. Once injected, the action of the 
chemical  agent  is, to  a  certain  extent,  uncontrollable  and  unpredictable.  This 
accounts  for  various  local  complications,  including  perforation, stricture 
formation, and ulceration. The destructive basis of sclerotherapy is emphasized by 
the  fact  that  ulcers  at  injection sites  are  expected to  occur in  all  patients.  The 
difference between an ulcer as a desirable consequence of therapy and one that 
represents  a  true  complication  is  merely  a  matter  of  degree and  the  clinical 
behavior of the lesion.  Unfortunately,  tissue damage probably also occurs with 
variceal ligation, although to a lesser degree than with sclerotherapy
Endoscopic Variceal Ligation:
Endoscopic  variceal  ligation  of  esophageal  varices  is  based on  a  technique 
developed in the 1950s for band ligation of hemorrhoids. As originally described 
by Stiegmann and colleagues (43),  use of this technique for esophageal varices 
involves  the  mechanical ligation  and  strangulation  of  variceal  channels  by 
application of small, elastic "O" rings. Several rings must be applied at various 
sites; because each ring must be loaded individually on the end of the endoscope, 
an overtube is used to allow rapid and repeated passage of the endoscope. Actual 
application of the ring to a varix is by means of an ingenious device attached to the 
distal end of a standard endoscope. Although a sequence of steps is required, most 
endoscopists find the technique for band ligation to be less demanding than that for 
sclerotherapy. 
Sclerotherapy Compared with Ligation:  
The work of Stiegmann and colleagues (44-48) on endoscopic variceal ligation 
may serve as a model for the development of new technology. Single-arm trials by 
this  group  have  shown  that  variceal  ligation is  comparable  to  endoscopic 
sclerotherapy in terms of control of variceal hemorrhage and the prevention of 
recurrent bleeding, but that variceal ligation has substantially less morbidity.
Although of good quality and credible, this work must be corroborated by other 
investigators. In the randomized, controlled trial reported by Laine and colleagues 
(49),  there  was  no  difference between variceal  ligation  and sclerotherapy with 
respect  to recurrent  variceal  bleeding,  volume  of  blood  transfused,  length of 
hospitalization,  and  survival.  Compared  with  patients  who had  sclerotherapy, 
however,  those  treated  with  ligation  had higher  Child-Pugh  scores  as  well  as 
varices  of  a  more  advanced endoscopic  grade.  In  the  only  other  randomized, 
controlled trial of ligation compared with sclerotherapy, Stiegmann and coworkers 
(50) showed a survival advantage for variceal ligation. In this study, patients were 
evenly matched for Child-Pugh score and variceal grade at endoscopy.
In  the  study  of  Laine  and  colleagues  (49),  variceal  ligation was  superior  to 
sclerotherapy with respect to local esophageal complications, especially stricture 
formation.  However,  the percentage  of  patients  (33%)  who  developed  an 
esophageal stricture as a result of sclerotherapy is remarkably high in this study. 
This  is  difficult  to  explain  but  may  be  due  to  the  use  of  a relatively  high 
concentration of the sclerosing agent. It is probable that the use of a less potent 
solution  would  have  resulted in  fewer  strictures,  although this  might  not  have 
prevented recurrent  bleeding  and  might  not  have  decreased  the  number  of 
treatment  sessions  required  for  variceal  eradication.  The  technique of  variceal 
ligation would seem to be inherently safe, but Laine and colleagues did encounter 
one patient who had an esophageal injury that appeared to be due to placement of 
the overtube. Although the risk for a "systemic" complication after variceal ligation 
should be  negligible,  bacteremia  has  been reported (51).  Variceal  ligation  also 
required statistically fewer treatment sessions for eradication of varices. 
Balloon tamponade:  
Balloon tamponade achieves control of variceal bleeding by direct pressure on the 
varices  and  can  be  life  saving  in  the  patient who  presents  with  massive 
haemorrhage. In experienced hands it is highly effective, with control of bleeding 
in 90% of cases. (52)  However, up to 50% of patients rebleed when the tube is 
deflated, and  there  is  an  associated  complication  rate  of  25-30% (53)  Serious 
complications  such  as  oesophageal  perforation  or  ulceration and  aspiration 
pneumonia may occur in up to 15% of patients. 
The  gastric  balloon  is  the  most  important  factor  for  controlling bleeding.  The 
balloon  is  inflated  with  120-200  ml  water  (containing a  small  amount  of 
radiographic contrast to enable it to be seen more easily on radiographs) and needs 
to be placed close to the oesophagogastric junction to arrest cephalad blood flow. 
We  use  a  tube  with  both  gastric  and  oesophageal  balloons  (Sengstaken-
Blakemore) but inflate the oesophageal balloons only if bleeding is not controlled. 
If gastric varices are the source of haemorrhage a tube with a single large (600 ml) 
gastric balloon (Linton- Nachlas) is more effective in stopping haemorrhage.(54) 
The balloon should not be inflated for more than 18 hours. Alternative, definitive 
treatment must be planned for when the balloon is deflated
Transjugular intrahepatic portosystemic shunt: 
TIPS is an angiographically created shunt between hepatic and portal veins that is 
kept open by placement of a fenestrated metal stent. It effectively decompresses 
the portal system, controlling active variceal bleeding over 90% of the time and 
achieving a mortality  rate of  less  than 10%, even in  critically  ill  patients  (55) 
Immediate  complications  include  secondary  bleeding  and,  in  20%  of  cases, 
worsening encephalopathy. The most common long-term complications are stent 
stenosis or occlusion that requires balloon angioplasty.  Causes of bleeding and 
recurrent portal hypertension after TIPS are summarized below.
Causes of bleeding and recurrent portal hypertension after TIPS: 
Stent dysfunction 
• Thrombosis 
• Retraction 
• Displacement 
• Stenosis 
Severe right-sided heart failure 
Hemobilia 
Persistent gastric varices 
• Associated with spontaneous splenorenal collaterals 
• Associated with massive splenomegaly 
As a consequence, TIPS is primarily used as rescue therapy when pharmacologic 
and endoscopic treatment of acute bleeding is unsuccessful. (56)
Prevention of complications and deterioration in liver function:
Infection Control and Treatment: 
Bacterial infections have been documented into 35-66% of patients with cirrhosis 
who  have  variceal  bleeding,  with  an  incidence  of  SBP  ranging  from  7-15%. 
However if only patients with ascites and gastrointestinal bleeding are considered, 
the incidence of SBP is very high. A recent meta-analysis has demonstrated that 
antibiotic prophylaxis significantly increased the mean survival rate (9.1% mean 
improvement  rate,  95%  CI:  2.9-15.3,p=.  004)  and  also  increased  the  mean 
percentage  of  patients  free  of  infection  (32%  mean  improvement  rate,  95% 
confidence interval: 22-42, p<. 001) (57). Finally our group has recently shown 
that  bacterial  infection,  diagnosed  on  admission,  is  an  independent  prognostic 
factor  of  failure  to  control  bleeding  or  early  rebleeding  (58).  These  data  may 
support a role of bacterial infection in the initiation of variceal bleeding (59). All 
cirrhotics  with  upper  gastrointestinal  bleeding  should  receive  prophylactic 
antibiotics whether sepsis is suspected or not. The optimal regimen is yet to be 
decided but oral or intravenous quinolones have been used. 
Ascites and renal function: 
Renal failure may be precipitated by a variceal bleed, usually due to a combination 
of  acute  tubular  necrosis,  and  hepatorenal  syndrome  (HRS)  associated  with 
deterioration in liver function and sepsis.  HRS is associated with an over 95% 
mortality. Thus any iatrogenic precipitants must be avoided.
The intravascular volume should be maintained preferably with Human Albumin 
Solution  or  blood  initially.  Normal  saline  should  be  avoided  as  it  may  cause 
further ascites formation.  Catheterisation of the bladder and hourly urine output 
measurement is mandatory and nephrotoxic drugs should be avoided, especially 
aminoglycosides and non-steroidal drugs.
Dopamine  was  the  first  drug  used  due  its  vasodilator  effect  when  given  in 
subpressor  doses.  Dopamine  is  frequently  prescribed  to  patients  with  renal 
impairment, and yet no studies have ever shown any convincing benefit (60,61) It 
is our impression that occasionally a patient responds with an increase in urine 
output.  It is therefore our practice to give a 12-hour trial of dopamine, and stop 
treatment if there has been no improvement of urine output. 
Increasing ascites may occur shortly after bleeding, but should not be the main 
focus  of  fluid  and electrolyte  management  until  bleeding  has  stopped and the 
intravascular volume is stable. If there is a rising urea and creatinine, all diuretics 
should  be  stopped,  and  paracentesis  performed  if  the  abdomen  becomes 
uncomfortable, re-infusing 8 gr. of albumin for every litre removed. 
When the patient has stopped bleeding for 24 hours, nasogastric feeding can be 
commenced with low sodium feed. This avoids the need for maintenance fluid, 
and removes the risk of line sepsis.
An unexplained rise in creatinine and urea may indicate sepsis. Evidence of sepsis 
should  be  sought  by  blood,  ascitic,  cannulae,  and  urine  culture,  and  non-
nephrotoxic  broad-spectrum  antibiotics  commenced,  regardless  of  evidence  of 
sepsis.  An undiagnosed delay  in  effective  treatment  of  infection  may  increase 
mortality.  In advanced cirrhosis,  endotoxins and cytokines play an increasingly 
important  role  in  advancing the  hyperdynamic circulation and worsening renal 
function (62) 
There  is  now increasing evidence for  the  use  of  vasopressin  analogues  in  this 
condition,  and the beneficial  effect  of  terlipressin with respect  to bleeding and 
survival  in  trials  to  date  may  be  through  the  prevention  of  this  catastrophic 
complication (63-65) 
Porto-systemic Encephalopathy:
The precipitant factors include: haemorrhage, sepsis, sedative drugs, constipation, 
dehydration, and electrolyte imbalance. These should be evaluated and corrected. 
Hypokalaemia,  hypomagnesaemia  and  hypoglycaemia  which  may  precipitate 
encephalopathy and should be aggressively corrected (e.g. a patient with ascites 
and a serum potassium of 3.0mmol/L is likely to require in excess of 100 mmol 
over 24 hours). As soon as the patient is taking oral fluid, lactulose 5-10mls QDS 
can be started. Phosphate enemas are also useful.
Alcohol withdrawal:
It  is  important  to  be  alert  to  the  possibility  of  withdrawal  from  the  patient’s 
history.  Encephalopathy  and  withdrawal  may  co-exist,  and  careful  use  of 
benzodiazepines may be required. Benzodiazepines or oral clormethiazole can be 
used.
Nutrition:
Only a few cirrhotics  are  not malnourished (66),  particularly  with severe  liver 
disease.  Often  they  do  not  want  to  eat,  are  “nil  by  mouth”  because  of 
investigations,  and  the  food  itself  maybe  "unappealing".  Thus  exacerbation  of 
malnutrition is common.
A fine bore nasogastric tube should be passed 24 hours after cessation of bleeding 
to commence feeding commenced.  There is no evidence that this may precipitate 
a  variceal  and it  allows  treatment  of  encephalopathy  in  comatose  patients  and 
makes  fluid  management  easier.  It  is  extremely  rare  that  parental  nutrition  is 
required. 
Vitamin replacement: All patients with a significant alcoholic history should be 
assumed to be folate and thiamine deficient, and be given at least three doses of 
the latter intravenously. It is easier and more practical to assume all such patients 
are  vitamin  deficient  rather  than  delay  treatment  whilst  awaiting  red  cell 
transketolase activity levels.  
Transfer of the Patient with Bleeding Varices and Use of Balloon Tamponade:
Inter-hospital  transfer  should  not  be  attempted  unless  the  bleeding  has  been 
controlled,  either  with vasopressor  agents/endoscopic  therapy or  tamponade.  If 
there is any suggestion of continued blood loss, and the source is known to be 
variceal, then a modified Sengstaken tube must be inserted prior to transfer. (i.e. 
with an oesophageal aspiration channel such as the Minnesota Tube) 
Duodenal varices: 
Duodenal varices occur in about 0.4% in all patients with portal hypertension and 
account for one third of bleeding episodes from ectopic varices. Early detection is 
important, as duodenal varices are a potential source of massive hemorrhage. At 
upper  gastrointestinal  endoscopy,  an  uninitiated  observer  may  misinterpret 
bleeding  from duodenal  varices  as  that  from duodenal  ulcer.  These  should  be 
considered  in  all  patients  with  duodenal  tumoral  lesions  and  suspected  portal 
hypertension. In this context, duodenal biopsy can be dangerous and should be 
avoided.  A diminution  in  the  volume of  the  duodenal  varices  with inspiratory 
movements  may  help  in  the  differential  diagnosis  during  endoscopy.
The  duodenal  bulb  is  the  most  common site  of  duodenal  varices,  the  second 
portion of the duodenum appears to be the next most common site but duodenal 
varices  in  the  other  portions  are  rare.  Hashizume  et  al.  studied  these  varices 
angiographically  and  histopathologically;  and  found  that  the  duodenal  varix 
consisted  of  a  single  vessel  with  afferent  and  efferent  vessels,  forming  a 
portosystemic shunt in the retroperitoneum. The varix traversed the duodenum and 
was present in the submucosal layer of the posterior wall; while the afferent vessel 
was the superior or inferior pancreaticoduodenal vein originating in the portal vein 
trunk or superior mesenteric vein, and the efferent vein drained into the inferior 
vena  cava.  They  have  also  been  reported  at  the  site  of  previous  duodenal 
operations  and  the  resultant  adhesions  and  after  endoscopic  sclerotherapy. 
Duodenal varices are more common in patients having extrahepatic portal vein 
obstruction  and  in  those  with  thrombosed  portosystemic  shunts.
Apart  from  endoscopy,  hypotonic  duodenography,  ultrasonography,  computed 
tomography, venous phase of superior mesenteric angiography, and percutaneous 
transhepatic  portography  have  been  used  to  diagnose  duodenal  varices.
Medical therapies, including vasopressin and octreotide may have limited success 
in  controlling  active  duodenal  variceal  bleeding.  Endoscopic  sclerotherapy  or 
endoscopic variceal ligations are the main treatment modalities. Embolization and 
transjugular  intrahepatic  portosystemic shunt  are  the  therapeutic  alternatives,  if 
endoscopic sclerotherapy or variceal ligation fails to control the bleeding. When 
conservative measures cannot control the hemorrhage, emergency laparotomy may 
be indicated. Duodenal varix suture ligation or resection results in a high rate of 
rebleeding.  End-to-side  portacaval  shunt  may  be  effective.  An  arteriovenous 
fistula requires resection of the paramural varix and surgical occlusion. In view of 
the difficulty  during the duodenal mobilization and the precarious condition of 
patient, it is not surprising that the operative mortality is high.
Jejunal and ileal varices:
A  triad  of  portal  hypertension  (generally  due  to  liver  cirrhosis),  history  of 
abdominal  surgery,  and hematochezia  without  hematemesis  characterizes  small 
intestinal  varices.  Bleeding  from varices  may present  with  vesical  varices  and 
gross hematuria if an intestinal segment is used for an augmentation cystoplasty. A 
history of abdominal surgery appears to predispose the development of ectopic 
varices  (portosystemic  communication)  in  adhesions.  Possible  physiological 
origins of this entity were studied in Edward's demonstration of network of fine 
communication  between  the  parietal  surface  of  the  viscera  and  the  posterior 
abdominal wall, arising in the embryo due to the juxtaposition of the developing 
systemic and visceral venous plexus. Formation of collaterals, de novo, is unlikely 
if the anatomy is undisturbed. In some cases no cause can be found. Histological 
examination demonstrates a massive varicose vein and several dilated veins in the 
submucosa. Although rare, bleeding from small bowel varices is associated with a 
high mortality as accurate preoperative diagnosis is often difficult. Detection of 
these  varices  has  been  a  challenging  task  and  several  invasive  diagnostic 
techniques such as enteroclysis, Tc-99m RBC studies, venous phase of mesenteric 
arteriography, enteroscopy, color flow Doppler ultrasound and magnetic resonance 
angiography have been used for this purpose. Intraoperative Sonde enteroscopy is 
safe and effective, providing complete visualization of the small-bowel mucosa 
without  enterotomy  while  avoiding  the  trauma  that  can  be  caused  by  push 
endoscopy. It is the diagnostic assessment of choice. Medical therapy, including 
vasopressin  infusion  via  the  superior  mesenteric  artery,  is  often  useful  in 
controlling acute variceal  bleeding.  Percutaneous transhepatic  embolization and 
transjugular  intrahepatic  portosystemic  shunt  are  the  therapeutic  alternatives. 
Surgical treatment consists of lysis of adhesions and bowel resection combined 
with portosystemic shunt, under the presumption that the portal pressure in these 
patients has been partially decompressed through these spontaneous shunts and 
may  increase  significantly  after  their  surgical  division.  Patients  with  excellent 
hepatic reserve survive and have no further gastrointestinal bleeding. 
Colonic varices:
Colonic  variceal  bleeding  is  a  rarity  and  is  most  commonly  due  to  portal 
hypertension, with local mesenteric vein obstruction constituting a rare cause. The 
true  prevalence  of  colonic  varices  is  not  known,  but  Feldman et  al.  found an 
incidence  of  0.07% in  autopsy  material.   Esophageal  varices  were  present  in 
approximately half of the group with colonic varices. Bleeding has been reported 
to  occur  in  2.5%  of  patients  attending  sclerotherapy  sessions  for  esophageal 
varices. In patients with portal hypertension the coronary azygous system was the 
primary portosystemic channel in at least half of the cases, but in a quarter of cases 
it  was  the  inferior  mesenteric-internal  iliac  system.  Possible  etiologies  of  this 
condition  may  be  esophageal  transection  and  devascularization  and  extensive 
thrombosis  of  the  portal  vein  resulting  in  obliteration  of  the  coronary-azygous 
anastomotic  system. In such a situation,  other  potential  sites  of  porto-systemic 
anastomoses,  such  as  that  in  the  colon,  may  open,  leading  to  development  of 
colonic varices. Idiopathic/primary, familial, secondary to splenic vein thrombosis 
and adhesion-related colonic varices without portal hypertension have also been 
reported.  Varices  of  the  colon  are  usually  segmental,  involving  predominantly 
(66%)  the  distribution  of  inferior  mesenteric  vein  and  less  frequently  in  the 
distribution of superior mesenteric area, and never confined to transverse colon. 
Diffuse variceal involvement of the colon is uncommon and implies an unknown 
cause. In case of colonic varices the differential diagnosis should include portal 
hypertension  with  chronic  liver  disease,  portal  vein  thrombosis,  vascular 
anomalies or postoperative complications. If this entity is not considered, a rectal 
or colonic biopsy may lead to brisk and dangerous bleeding. Apparent similarity 
of radiological and endoscopic appearance of varices to polyps, misdiagnosis and 
inappropriate biopsy remain the potential pitfalls. Colonoscopist visualizes these 
varices as serpiginious to nodular, often bluish submucous lesions. They are often 
missed on colonoscopy due to collapse of varices during periods of hypotension or 
because of increase in the intraluminal pressure due to air insufflation during the 
endoscopic  examination.  Sensitivity  of  colonoscopy  is  greatly  reduced  during 
periods  of  active  bleeding  and  in  the  absence  of  good  bowel  preparation.
In cases where the cause of lower GI bleeding is not clear, even after colonoscopy; 
venous phase of mesenteric angiogram and scintigraphic studies may be useful. If 
doubt persists, intraoperative colonoscopy may be useful to pinpoint the problem. 
Conservative therapy consists  of vasopressin and somatostatin analogue,  which 
may be useful in the control of bleeding. Sclerotherapy using a colonoscope and 
transjugular  intrahepatic  portosystemic  shunt  are  other  therapeutic  alternatives. 
The choice of surgical therapy in portal hypertension is portal decompression and 
not  colonic  resection;  as  colectomy  is  associated  with  significantly  greater 
mortality  due  to  risk  of  infection  and  considerable  technical  difficulty  of  this 
surgery in the presence of portal hypertension. 
Anorectal varices:
Anorectal varices are a rare cause of rectal bleeding and are often erroneously 
diagnosed as bleeding hemorrhoids. Although rare, rectum is the most common 
site of lower gastrointestinal varices. Rectal varices occur due to high pressure in 
the  inferior  mesenteric  venous  system  in  patients  with  portal  hypertension. 
Bleeding from them is uncommon, and often mild and self-limiting, but rarely it 
can be fatal. It is equally important to be aware of the presence of rectal varices in 
case rectal  biopsy is  needed in patients  with portal  hypertension.  The reported 
incidence  of  rectal  varices  ranges  from 40 to  89.3%.  No correlation  has  been 
found between the presence of anorectal varices and the Child's grade of cirrhosis, 
intrahepatic  V/s  extrahepatic  causes  of  portal  venous  obstruction,  the  grade  of 
esophageal  varices,  the  presence  of  gastric  varices,  portal  hypertensive 
gastropathy,  or  whether  or  not  patients  received  sclerotherapy.  Identifying  the 
source of lower gastrointestinal hemorrhage in patients with chronic liver disease 
and portal hypertension can be challenging but the differential diagnosis between 
hemorrhoids and anorectal varices has been elucidated in many studies. It has also 
been documented that the prevalence of hemorrhoids is not increased in patients 
with portal hypertension and their presence is unrelated to the degree of portal 
hypertension.  A  careful  examination  is  essential  to  prevent  misdiagnosis  and 
inappropriate and inadvertent treatment like surgical excision of varices in mistake 
for hemorrhoids, with disastrous results. Anorectoscopy is the initial investigation 
of  choice.  Rectal  endoscopic  ultrasonography,  transvaginal  sonography  and 
magnetic resonance imaging are useful in detecting the presence and number of 
rectal varices. The principal emergency treatment is endoscopic sclerotherapy or 
endoscopic ligation, failing which surgical ligation should be performed. Before 
the  advent  of  transjugular  intrahepatic  portosystemic  shunt  (current  choice  of 
treatment), a portosystemic shunt, preferably between the inferior mesenteric vein 
and  the  vena  cava  or  renal  vein,  was  the  treatment  of  choice.  Transjugular 
embolization of the inferior mesenteric vein is an alternative to TIPS, where TIPS 
is not feasible. 
Stomal varices:
Variceal  bleeding  from  enterostomy  is  an  unusual  complication  of  portal 
hypertension  and  represents  a  cause  of  recurrent  or  intractable  gastrointestinal 
bleeding.  Presence  of  caput  medusae/varices  developing  around  a  stoma  may 
herald the presence of mild to moderate portal hypertension before other signs of 
hepatic  decompensation  are  evident.  Once  variceal  communications  have  been 
formed between the portal venous system of the gut and subcutaneous systemic 
circulation, heavy bleeding from dilated venous plexus may occur spontaneously 
or from microtrauma. In a review, the average interval found was 48 months for 
ileostomies,  38  months  for  ileal  conduits  and  23  months  for  patients  with  a 
colostomy.  Proper  diagnosis  requires  careful  inspection  of  the  muco-cutaneous 
region of the stoma for venous bleeding sites and endoscopy examination of the 
stoma to rule out the presence of recurrent bowel disease or other lesions like 
arteriovenous malformations, polyp or Crohn's disease. The emergent treatment of 
bleeding  of  the  colostomy  must  combine  several  methods,  quite  often 
consecutively:  local  compression,  ligation,  and  sclerotherapy.  Palliative  local 
measures, like suture ligature or sclerotherapy, however, remain the treatment of 
choice  in  the  high-risk,  cirrhotic  patient  who  is  unlikely  to  survive  a  major 
operation and may increase the interval between bleeding episodes and decrease 
the severity of bleeding. The hemorrhage can be managed temporarily in most 
patients with local measures. Once bleeding is controlled, the treatment must be 
primarily medical (hygienic and dietary habits, b-adrenergic blocking agents), but 
complementary surgery is invariably necessary because of recurrence of bleeding. 
There is no consensus on which of the various surgical options is best, but by and 
large, the type of further surgical treatment is determined by the severity of the 
underlying  liver  disease  and  the  patient's  life  expectancy.  Mucocutaneous 
disconnection (MCD) is  simple,  quick,  repeatable  and associated with  a  lower 
morbidity and intraoperative blood loss than stomal relocation. In the select group 
of patients that cannot be managed conservatively, MCD is favored and relocation 
considered only if MCD is technically impossible i.e. improperly placed stoma, 
symptomatic peristomal hernias and those with poor appliance fit.  It  should be 
kept in mind that repeated use of local operative procedures leads to the formation 
of  scar  tissue and causes  problems in  the  care  of  the  stoma.  Although stomal 
manipulation is the most commonly performed procedure, portosystemic shunting 
has the lowest incidence of both rebleeding and need for additional procedures and 
provides the longest mean postoperative survival and is the choice in patients who 
are  good  surgical  candidates.  In  particular,  the  absence  of  postoperative 
encephalopathy in the ileostomy group may be attributed to the absence of colon, 
the  major  source  of  bacteria  generated  nitrogenous  products.  Transjugular 
intrahepatic  portosystemic  shunt  and  stomal  varices  embolization  are  effective 
alternatives in case of recurrent bleeding of stomal varices. The overall prognosis 
mainly  depends  on  the  function  of  the  liver,  the  deterioration  of  which  is 
accelerated by the successive hemorrhagic accidents. Particular attention should be 
paid to stoma care and the prevention of trauma from appliances.
Biliary varices
Gallbladder  varices  are  often  seen  in  portal  hypertension,  more  often  in  extra 
hepatic portal vein obstruction patients. Gallbladder varices do not correlate with 
size  of  esophageal  varices,  number  of  sessions  of  sclerotherapy,  presence  or 
absence of gastric  varices,  portal gastropathy, Child Pugh grade or splenorenal 
shunt  placement.  These  collaterals  cause  some  gallbladder  stasis  but  do  not 
impede gallbladder function and hence seem unlikely to contribute to gallstone 
formation. Their clinical significance is their propensity to bleed during biliary 
surgery;  thus,  the  operating surgeon should be aware  of  them. The color  flow 
Doppler is the gold standard procedure for the diagnosis, although angiography, 
computerized tomography and magnetic resonance have also been reported. Bile 
duct  varices are seen more frequently  in left  hepatic  duct,  possibly due to the 
joining  of  umbilical  vein  to  the  left  branch of  portal  vein  adjacent  to  the  left 
hepatic vein. The resultant filling defect in the ERCP has to be differentiated from 
sclerosing cholangitis and malignancy. Due to their propensity to bleed, balloon 
dilatation  is  probably  best  avoided  in  these  patients  and  placement  of  pigtail 
biliary endoprostheses  is  preferred over  straight  stents  with side flaps.  Usually 
biliary varices are found incidentally during imaging, but their presence calls for a 
search for portal vein thrombosis. Rarely they can give rise to obstructive jaundice 
or haemobilia.
Intraperitoneal hemorrhage from ectopic varices:
Intraperitoneal hemorrhage from ectopic varices is a rare occurrence. In cirrhotic 
patients,  sudden onset  of abdominal pain in combination with hypotension and 
falling  hematocrit  in  the  absence  of  external  blood  loss  should  result  in 
ultrasonography  of  the  abdomen.  The  main  differential  diagnosis  is  acute 
pancreatitis.  Any  free  fluid  present  should  be  aspirated  and  when  blood  is 
encountered  the  patient  must  be  operated  upon  immediately.  Spontaneous 
hemorrhage from anterior abdominal wall varices has also been documented into 
the rectus abdominus muscle and peritoneal cavity. Exploratory laparotomy and 
suture  ligation  of  the  bleeding  varix  seems  to  give  the  greatest  likelihood  of 
survival. Angiography with special attention to the venous phase may demonstrate 
the varices, in addition, vasopressin infusion in the superior mesenteric artery can 
be  tried,  which  may  permit  stabilizing  the  patient  before  surgery.  Patient's 
remaining  liver  function  and  the  ability  to  withstand  surgery  determine  the 
ultimate prognosis.
Cutaneous variceal bleeding:  
In  portal  hypertension,  three  types  of  cutaneous  portosystemic  collaterals  may 
develop the 'classical' Caput Medusae, enterostomal varices and scar or adhesion-
related abdominal collaterals. Very few cases have been documented of a varicose 
umbilical  vein  with  external  hemorrhage  significant  enough  to  cause 
hemodynamic  instability.  Coagulopathy  and  hemorrhagic  shock,  ending  in  a 
fatality may complicate the clinical course. Local measures (direct pressure, suture 
ligation and sclerotherapy) and medical  therapy should be applied early  in the 
resuscitation of the patient. Once stable, definitive treatment has to be instituted 
otherwise rebleeding is a certainty. Transjugular intrahepatic portosystemic shunt, 
umbilical vein embolization and mesocaval shunt surgery have all  shown good 
results, with stoppage of bleeding and disappearance of cutaneous varices. 
Miscellaneous:
Upper esophageal varices occur infrequently and may rarely cause massive upper 
gastrointestinal hemorrhage. This case serves to stress the importance of a through 
examination of the cervical portion of the esophagus during routine endoscopy. 
Varices of the gastric antrum are seen in a small proportion of patients and are 
distributed  equally  amongst  the  etiologies  of  portal  hypertension. They  rarely 
bleed and may be ignored during sclerotherapy of esophageal varices, however, if 
required, sclerotherapy is the treatment of choice. Rarely, idiopathic varices have 
been reported throughout the gastrointestinal tract. Significant varices can occur 
outside  the  gastrointestinal  tract  and  have  been  described  in  kidney,  lungs, 
tracheobronchial tree, mediastinum and vagina; giving rise to unusual hemorrhage 
as well as diagnostic difficulties on imaging.
                                       
                                      MATERIALS AND METHODS 
The  study  group  consisted  of  cirrhotic  patients  with  portal  hypertension 
(confirmed by ultra sound and Doppler study) registered and followed up at the 
liver clinic between January and June 2005. Patients who were on follow up for a 
minimum of one year until June 2006 were considered for analysis.
The following data were obtained at entry of the study: 
Age of the patient:  
Gender of the patient:
Duration of illness: i.e. duration in months up to the time of registration 
Details of treatment prior to registration (as a clue to duration of illness).  In 
asymptomatic  individuals,  the  date  of  confirmed  diagnosis  on  ultrasound  was 
considered as the date of first presentation.   
Etiology of cirrhosis was arrived based on history of alcohol intake including 
quantity  & total  duration of  consumption;  blood for  viral  serology (HBsAg & 
HBV DNA assay for hepatitis B and HCV RNA & Anti-HCV for hepatitis C); 
serum caeruloplasmin (< 20mg%), presence of Kayser Fleischer ring and 24 hours 
urine  copper  estimation  (>100mg%)  for  Wilson’s  disease;  and  antinuclear 
antibody, hyper gammaglobulinemia (>3.5gm%) for autoimmune related cirrhosis. 
Apart from details of past blood transfusion, surgery, family members with liver 
disease,  details  of  associated  co-morbid  illness were  also  recorded.  Diabetes 
mellitus was diagnosed when the fasting  blood sugar was greater than 120 mg% 
or  a  postprandial  value  exceeded 200mg%;  essential  hypertension  when blood 
pressure was more than 130/85 mm of Hg; hypothyroid state when T3 & T4 levels 
were low and with an elevated TSH.  Renal disease was considered when the 
blood urea and serum creatinine values were greater than 40mg/dL and 0.9 mg/dL 
respectively. 
Child Turcot Pugh (CTP) score  was applied to grade the severity of cirrhosis. 
CTP score is based on serum bilirubin, serum protein, ascites, prothrombin time 
and hepatic encephalopathy.
Childs A
(score 1)
Childs B
(score 2)
Childs C
(score 3)
Serum bilirubin < 2mg% 2 -  3mg% > 3mg%
Serum protein > 3.5 gm% 2.8  -  3.4 gm% < 2.8 gm%
Ascites Nil Mild Moderate to severe
Prothrombin time < 14 seconds 15- 17 seconds > 18 seconds
Encephalopathy Nil Mild to moderate Moderate to severe
In primary biliary cirrhosis and primary sclerosing cholangitis alone the following 
serum bilirubin values are considered for scoring.  
Childs A
(score 1)
Childs B
(score 2)
Childs C
(score 3)
Serum bilirubin < 4mg% 4 - 10mg% > 10mg%
Minimum score of CTP is 5 and maximum score is 15. Based on scoring system, 
cirrhosis was classified as Childs A when the total score was 5 and 6, Childs B 
when the total score was 7 to 9 and Childs C when the total score is exceeded 9. 
Details of index and subsequent bleed: Index bleed was defined as an individual 
who had a first variceal bleed in his/or her life time. Bleed either early or late 
following an index bleed was labeled as a subsequent bleed. 
For study purpose, a bleeder was defined as one who had registered as a bleeder at 
the initiation of the study or had a bleed atleast once during the study period.
Grades of esophageal varices:  It  was assessed by using upper endoscopy and 
Paquet’s grading for esophageal varices was applied. 
1. Grade I:   Small varices without luminal prolapse
2. Grade II: Moderate varices with luminal prolapse and minimal obscuring of 
OG junction.
3. Grade III: Large varices substantially obscuring the OG junction.
4. Grade IV: Very large varices completely obscuring the OG junction.
Varices seen in fundus of the stomach is labeled as fundal varices. It is classified 
as tortuous type, nodular type and tumouros type. 
Presence or absence of red signs such as red wheal sign, cheery red spots were 
documented , all indicators of an imminent bleed.  
Blood chemistry included:
Liver function tests such as serum bilirubin (direct as well as indirect fraction), 
aspartate  &  alanine  transaminase,  serum  total  protein  including  albumin  and 
globulin  and  prothrombin  time,  renal  function  tests.  Baseline  serum 
alphafetoprotein was estimated in all the patients at time of registration and once 
in every 6-months. 
The  management protocol of the bleeders and non bleeders was based on the 
grades  of  varices.  Irrespective  of  grades  of  varices  all  bleeders  had  serial 
sclerotherapy at three weekly intervals until obliteration of varices in combination 
with  propranolol  20  mg  twice  a  day.  Those  with  fundal  varices  were  on 
propranolol 40 mg twice a day in combination with isosorbide mononitrate 20 mg 
once a day. Non bleeders with varices-grades III and IV had primary prophylaxis 
with propranolol 20 mg twice a day. Due to economic constraints, EVL the current 
recommended procedure, was not advocated for primary endoscopic prophylaxis.
Individuals  were  followed up at  monthly  intervals  for  variceal  bleed,  cirrhosis 
related  complications  such  as  spontaneous  bacterial  peritonitis,  hepatorenal 
syndrome, encephalopathy and hepatoma.
Statistical analysis
Demographic and clinical data were expressed as frequency with their percentage. 
Bi-variate analysis of Pearson’s Chi - squared test, Yates corrected Chi – squared 
test  and  Fisher’s  exact  test  were  used  for  calculating  differences  in  the 
demographic and clinical data between the variceal bleeders and the non bleeders. 
Logistic regression multivariate analysis was used to identify the significant risk 
factors.                                                    
   
                                               
                                                     
                                        OBSERVATION AND RESULTS 
205 of the 223 patients registered until 30th June 2005, fulfilled the criteria and 
completed the study. 18 patients were lost to follow up and could not be contacted. 
There were 145 male and 60 female patients.  The mean age for men was 44 + 
15.1 yrs and for women 43 + 14.3 yrs. There were 95 cirrhotics who had a variceal 
bleed during the study period and 110 were nonbleeders.  The male female ratio in 
the two groups was 2:1 and 2.9:1 respectively. 
Amongst  the  bleeders,  63  (66.3%)  were  male  and  32  (33.7%)  were  female. 
Regarding  etiology  of  cirrhosis,  in  descending  order  of  frequency,  unknown 
etiology contributed to 43.1%, ethanol to 27.3%, virus related to 24.2% and others 
5.2%. Endoscopic esophageal varices Grade I & II and grade III & IV were seen 
in  38.9% and 61.1% respectively.  The frequency of cherry red spots was 5.2% 
and fundal  varices  was  18.9%.  Diabetes  mellitus  was  co-existing  in  9.5% and 
essential hypertension in 6.3%.  73.7% belonged to Childs A, 26.3% to Childs B. 
There were none with Childs C.   
Amongst  the non bleeders,  89 (80.9%) were male and  21(19.1%)  were female. 
The cause for cirrhosis was,  virus related in 44.5%,  unknown in 25.5%, ethanol 
related in 24.5%, and others (5.5%) in descending order of frequency. Endoscopic 
esophageal  varices  grade  I  & II  and  grade  III  & IV  were  85.5% and  14.5% 
respectively.  The frequency of cherry red spots was present in only one case; five 
had  fundal  varices.  Co-existing  diabetes  mellitus  was  present  in  15.5%  and 
hypertension in  4.5%. 29.1% belonged to Childs A, 66.4% to Childs B and 4.5% 
to Childs C.  
Table I summarizes the duration of illness,  the etiology, the co-morbid disease 
states  and  predictors  of  variceal  bleed  in  the  two  groups.  An  average  of  six 
sessions of sclerotherapy (range varies from 4 to 9) downgraded the varices to 
grade I. One patient with fundal variceal bleed and failed sclerotherapy required 
emergency devascularisation. 
On univariate analysis, age of presentation, gender, established etiological factors 
and co morbid illness did not influence the risk of a variceal bleed. Unknown 
etiology (p-0.006), higher grades of varices (III and IV) (p -0.001), presence of 
cherry red spots (p-0.03),  fundal varices (p-0.001) and Childs A CPT score (p 
-0.04) had significant influence over the bleed rates.
Multivariate analysis (Table II) showed that patients with lower grade of varices (I 
& II) had 4 - times lower risk of bleed and the presence of fundal varices placed 
the patients at a three - fold increased risk. However unknown etiology, cherry red 
spot and CPT score did not affect the rebleed rates.
Among the bleeders, 70 variceal bleeders presented with an index bleed and all 
belonged to Childs A; 38 of them progressed to Childs B (54.28%). Subsequent 
variceal bleed occurred in 27 patients. The mean interval between the first and 
second variceal bleed in this subgroup was 8 + 7.7 months. 14 patients bled for a 
third time after a mean interval of 7 + 12.5 months. 13 patients had no further 
variceal bleed (48.15%).  The risk factors that influenced the subsequent bleeds 
were  similar  to  that  of  the  initial  bleed  except  that  the  CPT  score  had  now 
progressed  to  Childs  B.    Two  deaths  occurred  due  to  a  variceal  bleed:  one 
following surgery and the other due to failed medical and endotherapy; one each 
succumbed  to  hepatic  encephalopathy,  hepatorenal  syndrome  and  hepatoma.  
Three developed spontaneous bacterial peritonitis.
Twenty-five (18.5%) patients who had not bled at the time of registration, bled for 
the first time after a mean period of 7 + 8.6 months (range 1 - 15 months) during 
the 18 month follow up. Two had a second bleed at a mean interval of 5 months. 
Comparing index bleeders and bleeders on follow-up, except CPT score there is 
no significant difference (Table III). Four succumbed to hepatic encephalopathy 
and  two  to  hepatorenal  syndrome.  None  developed  spontaneous  bacterial 
peritonitis or hepatocellular carcinoma.
                                                     
                                                 
                                                   DISCUSSION
Esophageal variceal bleed is common in 30% of cirrhotic patients, with a one year 
mortality of 50% after the initial bleed.1-6 The greatest risk is during the first 48 to 
72 hours and more than 50% of all early rebleed episodes occur within the first 10 
days after cessation of active hemorrhage.7-9 
The  present  study  has  prospectively  looked  into  the  bleed  pattern  amongst 
cirrhotics with portal hypertension in a south Indian population. The statistically 
significant variables which differentiated a variceal bleeder from a non bleeder 
during  the  18  month  follow-up were  large  sized  varices,  cherry  red  spots  and 
fundal varices both for the index bleeders and subsequent bleeders. The results are 
similar to that reported by other workers (67,68). Kleber et al (69) however, found 
that CTP score did not influence the bleed rates but did influence the mortality. 
A high risk of index bleed has been attributed to continued alcohol use, poor liver 
function  (Child-Pugh  Class  C)  and  ascites  (69). Alcohol  and  viruses  did  not 
increase the risk of index bleed in the present series, unlike the reports by others 
(70).   
A high incidence of rebleed rate (30–50%) has been documented after endoscopic 
sclerotherapy  (71-73).  Attributable  factors  include  age  greater  than  60  years, 
hemoglobin of less than 8 gm/dL, large varices, clot on varices, actively bleeding 
varices,  renal  failure and ascites (70,74).  The rebleed rate at  18 months in the 
present  series  was  29.4%  figures  similar  to  North  Italian  Endoscopic  Club 
multicentric report (NIEC)(75) of 26.5% over a median period of 23 months and 
other studies (66,67).  The risk factors for variceal rebleed in the present series 
were similar to that of the initial bleed and not much of difference was noted in the 
interval between the first and second and between second and third bleed, results 
comparable to the NIEC report.
Survival rates after index bleed without treatment has varied from 32-80% (76,77). 
Each subsequent bleed is associated with at least a 20% to 30% risk of death (70). 
Mortality rate in our series was 2% following sclerotherapy; both the patients had 
two subsequent bleeds. Summarizing, the risk of variceal bleed amongst cirrhotics 
in  our  series  is  directly  related to the  grades of  varices,  results  similar to  that 
reported in the west. Variceal rebleed rates and bleed related mortality is low in an 
era of sclerotherapy
SUMMARY & CONCLUSION
Esophageal variceal bleed pattern in 205 cirrhotics were studied between January 
2005 to June 2006.  
Age and gender  did not  influence the bleed pattern amongst bleeders  and non 
bleeders.
Though unknown etiology among bleeders and viral related etiology among non 
bleeders were common causes for cirrhosis, it was not significant.
Higher grades of varices, presence of cherry red spots and fundal varices were the 
predictors of variceal bleed in liver cirrhosis. 
The risk factors that influenced the subsequent bleeds were similar to that of the 
initial bleed.
There was no role for co-morbid diseases such as diabetes and hypertension in 
variceal  bleed and bleed related mortality. 
Most  of index bleeders belonged to  Childs A and became Childs  B following 
bleed.  Variceal bleed related mortality following endoscopic sclerotherapy was 
low. 
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